NICE Does Not Recommend These Two Cancer Medicines for Treating Patients
The National Institute for Health and Care Excellence (NICE) does not recommend these two drugs gilteritinib (Xospata) and pembrolizumab (Keytruda) for NHS use. The decisions about both the drugs will be reviewed at the end of this year until the drug manufacturers have time to prepare the strong arguments about the drug usage and collect…